JP2004509061A5 - - Google Patents

Download PDF

Info

Publication number
JP2004509061A5
JP2004509061A5 JP2001559475A JP2001559475A JP2004509061A5 JP 2004509061 A5 JP2004509061 A5 JP 2004509061A5 JP 2001559475 A JP2001559475 A JP 2001559475A JP 2001559475 A JP2001559475 A JP 2001559475A JP 2004509061 A5 JP2004509061 A5 JP 2004509061A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
pharmaceutically acceptable
hepatitis
virus
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001559475A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004509061A (ja
JP4975930B2 (ja
Filing date
Publication date
Priority claimed from US09/595,365 external-priority patent/US6455508B1/en
Application filed filed Critical
Publication of JP2004509061A publication Critical patent/JP2004509061A/ja
Publication of JP2004509061A5 publication Critical patent/JP2004509061A5/ja
Application granted granted Critical
Publication of JP4975930B2 publication Critical patent/JP4975930B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2001559475A 2000-02-15 2001-02-15 カルボキサミジンで修飾した単環式塩基を有するヌクレオシドアナログ Expired - Fee Related JP4975930B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18267600P 2000-02-15 2000-02-15
US60/182,676 2000-02-15
US09/595,365 2000-06-16
US09/595,365 US6455508B1 (en) 2000-02-15 2000-10-05 Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides
PCT/US2001/040148 WO2001060379A1 (en) 2000-02-15 2001-02-15 Nucleoside analogs with carboxamidine modified monocyclic base

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009018382A Division JP5253204B2 (ja) 2000-02-15 2009-01-29 カルボキサミジンで修飾した単環式塩基を有するヌクレオシドアナログ

Publications (3)

Publication Number Publication Date
JP2004509061A JP2004509061A (ja) 2004-03-25
JP2004509061A5 true JP2004509061A5 (https=) 2006-01-05
JP4975930B2 JP4975930B2 (ja) 2012-07-11

Family

ID=26878297

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2001559475A Expired - Fee Related JP4975930B2 (ja) 2000-02-15 2001-02-15 カルボキサミジンで修飾した単環式塩基を有するヌクレオシドアナログ
JP2001559477A Pending JP2004510691A (ja) 2000-02-15 2001-02-15 カルボキサミジンで修飾した二環式塩基を有するヌクレオシドアナログ
JP2009018382A Expired - Fee Related JP5253204B2 (ja) 2000-02-15 2009-01-29 カルボキサミジンで修飾した単環式塩基を有するヌクレオシドアナログ

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2001559477A Pending JP2004510691A (ja) 2000-02-15 2001-02-15 カルボキサミジンで修飾した二環式塩基を有するヌクレオシドアナログ
JP2009018382A Expired - Fee Related JP5253204B2 (ja) 2000-02-15 2009-01-29 カルボキサミジンで修飾した単環式塩基を有するヌクレオシドアナログ

Country Status (28)

Country Link
US (1) US6455508B1 (https=)
EP (3) EP1813278B9 (https=)
JP (3) JP4975930B2 (https=)
KR (2) KR100811927B1 (https=)
CN (2) CN1268335C (https=)
AT (1) ATE377422T1 (https=)
AU (2) AU783142B2 (https=)
BR (2) BR0108401A (https=)
CA (2) CA2395854A1 (https=)
CY (1) CY1107103T1 (https=)
CZ (2) CZ302327B6 (https=)
DE (1) DE60131250T8 (https=)
DK (1) DK1257281T3 (https=)
ES (2) ES2295148T3 (https=)
HR (2) HRP20020583A2 (https=)
HU (2) HU229480B1 (https=)
IL (3) IL150555A0 (https=)
MX (2) MXPA02007932A (https=)
NO (2) NO329927B1 (https=)
NZ (2) NZ521390A (https=)
PL (2) PL365239A1 (https=)
PT (1) PT1257281E (https=)
RS (1) RS20090086A (https=)
RU (2) RU2259831C2 (https=)
SI (2) SI21077A (https=)
SK (2) SK287765B6 (https=)
WO (2) WO2001060379A1 (https=)
YU (1) YU61502A (https=)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6831069B2 (en) * 1999-08-27 2004-12-14 Ribapharm Inc. Pyrrolo[2,3-d]pyrimidine nucleoside analogs
US7638496B2 (en) * 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
US7056895B2 (en) * 2000-02-15 2006-06-06 Valeant Pharmaceuticals International Tirazole nucleoside analogs and methods for using same
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
KR20080021797A (ko) 2000-05-26 2008-03-07 이데닉스(케이만)리미티드 플라비바이러스 및 페스티바이러스의 치료방법 및 조성물
WO2002057425A2 (en) 2001-01-22 2002-07-25 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2003037908A1 (en) * 2001-10-31 2003-05-08 Ribapharm Inc. Antiviral combination therapy and compositions
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
PL374781A1 (en) 2002-06-28 2005-10-31 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
HUE033832T2 (en) 2002-11-15 2018-01-29 Idenix Pharmaceuticals Llc 2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
RU2005121904A (ru) 2002-12-12 2006-01-20 Айденикс (Кайман) Лимитед (Ky) Способ получения 2`-разветвленных нуклеозидов
RU2005133093A (ru) * 2003-03-28 2006-07-27 Фармассет, Инк. (Us) Соединения для лечения флавивирусных инфекций
US20040197292A1 (en) * 2003-04-04 2004-10-07 The Procter & Gamble Company Personal care composition containing an antidandruff component and a nonionic surfactant
US20040202636A1 (en) * 2003-04-11 2004-10-14 Kaczvinsky Joseph Robert Personal care composition containing an antidandruff component and a nonionic surfactant
US20040197287A1 (en) * 2003-04-04 2004-10-07 The Procter & Gamble Company Personal care composition containing an antidandruff component and a nonionic surfactant
US6930093B2 (en) * 2003-07-10 2005-08-16 Valeant Research & Development Use of ribofuranose derivatives against inflammatory bowel diseases
US20050009848A1 (en) * 2003-07-10 2005-01-13 Icn Pharmaceuticals Switzerland Ltd. Use of antivirals against inflammatory bowel diseases
WO2005018330A1 (en) * 2003-08-18 2005-03-03 Pharmasset, Inc. Dosing regimen for flaviviridae therapy
US20050095218A1 (en) * 2003-10-29 2005-05-05 The Procter & Gamble Company Personal care composition containing a detersive surfactant, an antidandruff component, and ketoamide surfactants
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
AU2005254057B2 (en) 2004-06-15 2011-02-17 Isis Pharmaceuticals, Inc. C-purine nucleoside analogs as inhibitors of RNA-dependent RNA viral polymerase
JP4516863B2 (ja) * 2005-03-11 2010-08-04 株式会社ケンウッド 音声合成装置、音声合成方法及びプログラム
CA2606195C (en) 2005-05-02 2015-03-31 Merck And Co., Inc. Hcv ns3 protease inhibitors
AR057456A1 (es) 2005-07-20 2007-12-05 Merck & Co Inc Inhibidores de la proteasa ns3 del vhc
NZ565269A (en) 2005-08-01 2010-03-26 Merck & Co Inc Macrocyclic peptides as HCV NS3 protease inhibitors
EP1976382B1 (en) 2005-12-23 2013-04-24 IDENIX Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
US8497292B2 (en) 2005-12-28 2013-07-30 Translational Therapeutics, Inc. Translational dysfunction based therapeutics
WO2007123579A2 (en) * 2005-12-28 2007-11-01 Translational Therapeutics Translational dysfunction based therapeutics
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
WO2008005542A2 (en) * 2006-07-07 2008-01-10 Gilead Sciences, Inc., Antiviral phosphinate compounds
AU2007309488B2 (en) 2006-10-24 2012-10-11 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
CA2667146C (en) 2006-10-24 2016-01-19 Merck & Co., Inc. Hcv ns3 protease inhibitors
AU2007309546A1 (en) 2006-10-24 2008-05-02 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. HCV NS3 protease inhibitors
BRPI0718161A2 (pt) 2006-10-27 2013-11-26 Merck & Co Inc Composto, composição farmacêutica, e, uso do composto.
US8377874B2 (en) 2006-10-27 2013-02-19 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
GB0625345D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
CA2672250C (en) 2006-12-20 2013-04-30 Ian Stansfield Antiviral indoles
GB0625349D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
JP2010533699A (ja) 2007-07-17 2010-10-28 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー C型肝炎感染症の治療のための大環状インドール誘導体
AU2008277377B2 (en) 2007-07-19 2013-08-01 Msd Italia S.R.L. Macrocyclic compounds as antiviral agents
WO2009134624A1 (en) 2008-04-28 2009-11-05 Merck & Co., Inc. Hcv ns3 protease inhibitors
EA019327B1 (ru) 2008-07-22 2014-02-28 Мерк Шарп Энд Домэ Корп. Макроциклическое хиноксалиновое соединение в качестве ингибитора протеазы вгс ns3
WO2010082050A1 (en) 2009-01-16 2010-07-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections
GB0900914D0 (en) 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
US8828930B2 (en) 2009-07-30 2014-09-09 Merck Sharp & Dohme Corp. Hepatitis C virus NS3 protease inhibitors
EP2780026B1 (en) 2011-11-15 2019-10-23 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
WO2013106344A1 (en) 2012-01-12 2013-07-18 Ligand Pharmaceuticals, Inc. 2 '-c-methyl nucleosides containing a cyclic phosphate diester of 1, 3-propanediol (2-oxo-[1, 3, 2]-dioxaphosphorinane) at position 5'
CN102978264B (zh) * 2012-11-14 2014-12-10 广东肇庆星湖生物科技股份有限公司 一种他立韦林的制备方法
WO2014121418A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
WO2014121417A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
JP2017512183A (ja) 2014-02-13 2017-05-18 リガンド・ファーマシューティカルズ・インコーポレイテッド プロドラッグ化合物およびそれらの使用
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
EA201890454A1 (ru) * 2015-08-06 2018-07-31 Чимерикс, Инк. Пирролопиримидиновые нуклеозиды и их аналоги, которые можно использовать в качестве противовирусных средств
WO2019060692A1 (en) 2017-09-21 2019-03-28 Chimerix, Inc. MORPHIC FORMS OF 4-AMINO-7- (3,4-DIHYDROXY-5- (HYDROXYMETHYL) -ETRAHYDROFURAN-2-YL) -2-METHYL-7H-PYRROLO [2,3-D] PYRIMIDINE-5-CARBOXAMIDE AND THEIR USES
RU2020126177A (ru) 2018-01-09 2022-02-10 Лиганд Фармасьютикалз, Инк. Ацетальные соединения и их терапевтическое применение

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3984396A (en) 1971-06-01 1976-10-05 Icn Pharmaceuticals, Inc. 1-(β,-D-ribofuranosyl)-1,2,4-triazole acid esters
US3798209A (en) 1971-06-01 1974-03-19 Icn Pharmaceuticals 1,2,4-triazole nucleosides
US3991078A (en) 1971-06-01 1976-11-09 Icn Pharmaceuticals, Inc. N-substituted 1,2,4-triazoles
USRE29835E (en) 1971-06-01 1978-11-14 Icn Pharmaceuticals 1,2,4-Triazole nucleosides
US3962211A (en) * 1975-01-13 1976-06-08 The University Of Utah 7-substituted nucleoside compounds
US4093624A (en) 1977-01-31 1978-06-06 Icn Pharmaceuticals, Inc. 1,2,4-Thiadiazolidine-3,5-dione
SU1124559A1 (ru) * 1983-06-08 1986-07-07 Институт молекулярной биологии АН СССР 1-(2-Оксиэтоксиметил)-1,2,4-триазол-5-карбоксамид,обладающий активностью противвируса герпеса
JPS6426593A (en) 1987-07-21 1989-01-27 Asahi Glass Co Ltd Nucleoside derivative
US4892865A (en) * 1987-12-01 1990-01-09 The Regents Of The University Of Michigan Pyrrolo[2,3-d]pyrimidine nucleosides as antiviral agents
US5405837A (en) * 1993-05-18 1995-04-11 Indiana University Foundation Method for the treatment of neoplastic disease utilizing tiazofurin and ribavirin
RU2186569C2 (ru) * 1996-01-23 2002-08-10 Ай-Си-Эн ФАРМАСЬЮТИКАЛЗ Модуляция экспрессии тн1/тн2 цитокинов рибавирином и аналогами рибавирина в активированных т-лимфоцитах
US5767097A (en) * 1996-01-23 1998-06-16 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
IL129126A0 (en) * 1996-10-16 2000-02-17 Icn Pharmaceuticals Monocyclic l-nucleosides analogs and uses thereof
WO2001027114A1 (en) * 1999-08-27 2001-04-19 Icn Pharmaceuticals, Inc. PYRROLO[2,3-d]PYRIMIDINE NUCLEOSIDE ANALOGS

Similar Documents

Publication Publication Date Title
JP2004509061A5 (https=)
RU2002120922A (ru) Нуклеозидные аналоги с карбоксамидин-модифицированным моноциклическим основанием
JP2003526662A5 (https=)
JP2004504406A5 (https=)
JP2003526673A5 (https=)
WO2003063771A3 (en) N4-acylcytosine nucleosides for treatment of viral iinfections
JP2021100937A5 (https=)
JP2008514732A5 (https=)
JP2003501474A5 (https=)
JP2002543144A5 (https=)
RU95117097A (ru) ПРИМЕНЕНИЕ ДИДЕЗОКСИ-АНАЛОГОВ НУКЛЕОЗИДОВ ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ, СПОСОБ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ, β -Z-5-ФТОР-2',3'-ДИДЕЗОКСИЦИТОЗИН И ЕГО ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМЫЕ ПРОИЗВОДНЫЕ
JP2003503449A5 (https=)
JP2005508337A5 (https=)
JP2002527522A5 (https=)
JPWO2021050956A5 (https=)
JP2003514025A5 (https=)
RU2002112248A (ru) Лечение вирусных инфекций с использованием левовирина
JPWO2019200005A5 (https=)
JP2021523129A5 (https=)
CA2368352A1 (en) Method for treating neurodegeneration
JP2003512421A5 (https=)
JP2004529158A5 (https=)
JP2005509615A5 (https=)
JP2007516296A5 (https=)
JP2018131439A5 (https=)